CD4 and non-Hodgkin lymphoma: Consistent with predominantly older studies focusing on cancer overall rather than individual cancers, we found that higher CD4 counts significantly decreased mortality rates after NHL, as well as after anal and lung cancers [40,41]; predictors of mortality were not assessed after KS and prostate cancer due to low mortality rates.